GENETIC ENGINEERING APPROACHES FOR MALARIA VACCINES
GENETIC ENGINEERING APPROACHES FOR MALARIA VACCINES
批准号:
3488465
负责人:
PHILIP JEFFREYJ BARR
金额:
$5.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1986
资助国家:
美国
项目状态:
已结题
起止时间:
1986-03-01 至 1986-08-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Subunit vaccines for the two predominant species of malaria parasites,
Plasmodium falciparum and Plasmodium vivax will be developed. We have
demonstrated that hybrid Hepatitis B virus surface antigen (HBVsAg)
polypeptides (composed of insertions of part of the circumsporozoite gene
of P. falciparum into the pre-S region of the HBVsAg gene) are expressed in
genetically engineered yeast vector systems. These hybrid polypeptides
assemble into multimeric particles that have antigenicities of both HBV and
the malaria parasite. We propose to produce hybrid HBV polypeptides
containing parts of the circumsporozoite gene of P. vivax. We also propose
to use yeast expression vectors to produce the entire circumsporozoite
proteins of both malaria species. In Phase I, the antigenicity of the
hybrid HBVsAg particles and circumsporozoite proteins made in yeast will be
assessed with antisera to the malaria parasite; hyperimmune human sera and
various animal sera raised to either intact parasites or to synthetic
peptides representing the repeat units of the circumsporozoite antigen will
be tested. Also, the immunogenicity of these preparations will be
evaluated in rodents and in sub-human primates. These studies will focus
on measuring immune responses that correlate with protection. For Phase
II, expression systems will be optimized and purification procedures will
be developed to produce large quantities of the most immunogenic form of
these malaria antigen(s). Challenge studies will be conducted in sub-human
primates. Various immunization procedures as well as the effects of
adjuvants will be tested. The results of these challenge experiments will
be used to determine whether or not antigens of other stages of the
parasites' life cycles should be included to stimulate effective and
durable immunity. The procedures developed in Phase I, testing the use of
hybrid HBVsAg as a carrier for presentation of portions of the
circumsporozoite antigen and testing the entire circumsporozoite protein
expressed in yeast, may provide the means to augment the immunogenicity of
the surface proteins of merozoite and gametocyte stages of malaria
parasites.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Muramyl peptide adjuvants for Plasmodium falciparum and Plasmodium vivax circumsporozoite vaccines in rodent model systems.
用于啮齿动物模型系统中恶性疟原虫和间日疟原虫环子孢子疫苗的胞壁酰肽佐剂。
DOI:
--
发表时间:
1992
期刊:
Biotechnology therapeutics
影响因子:
--
作者:
[Bathurst,IC, Gibson,HL, Kansopon,J, Hahm,BK, Hollingdale,MR, Barr,PJ]
通讯作者:
Barr,PJ
GENETIC ENGINEERING APPROACHES FOR MALARIA VACCINES
-
批准号:3505980
-
项目类别:
-
资助金额:$25.91万
-
财政年份:1988
-
负责人:PHILIP JEFFREYJ BARR
-
依托单位:
GENETIC ENGINEERING APPROACHES FOR MALARIA VACCINES
-
批准号:3505981
-
项目类别:
-
资助金额:$24.09万
-
财政年份:1988
-
负责人:PHILIP JEFFREYJ BARR
-
依托单位:
海外基金